University of Minnesota

University of Pennsylvania

The University of North Carolina at Chapel Hill

Other

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Chiron Corporation

St. Jude Children's Research Hospital

University of Nevada

Albert-ludwigs-universitat Freiburg

University of Michigan

New York University

The Ohio State University

The University of New Mexico

The UAB Research Foundation (The University of Alabama at Birmingham)

Albert-ludwigs-universitaet Freiburg

Bruce Robert Blazar

Jakub Tolar

Carl H June

James L Riley

William J Murphy

Keli Hippen

Mark J Osborn

Bruce L Levine

Daniel F Voytas

Daniel A Vallera

Wayne R Godfrey

Thomas R Kozel

Richard G Carroll

Julie A Lovchik

Patricia Taylor

Jeff S Miller

Ann Percival

Suzanne Brandt

Peter Thorkildson

Beau R Webber

Robert H Wiltrout

Robert Zeiser

C Rick Lyons

Susan Wilson

Jenny P Y Ting

Peter J Murray

Brent Koehn

Catherine M Verfaillie

Donald J Buchsbaum

Ramiro Garzon

Jonathan Serody

Alexandra Zanin-Zhorov

Ryan Flynn

Angela Panoskaltsis-Mortari

James M Coghill

Pavan Reddy

Benjamin Vincent

Michael Verneris

C Richard Lyons

Dharmeshkumar Patel

Heather Stefanski

Danny Bruce

Yong-Oon Ahn

James Muller

Tom Neubert

Sudha Kumari

Michael Dustin

Cameron McDonald-Hyman

Yaping Sun

Ryan P Flynn

Christopher A Pennell

Brent H Koehn

Induced pluripotent stem cells (iPSCs) derived from a T cell of a T cell subset. T cells derived from iPSCs derived from a T cell. Methods of deriving iPSCs from a T cell. Methods of deriving T cells from iPSCs including deriving a T cell of a T cell subset from an iPSC. Methods of engineering chimeric antigen receptor (CAR)-expressing or T cell receptor (TCR)-expressing iPSC. Methods of administering T cells derived using the methods disclosed. Induced pluripotent stem cell lines derived from T cells, methods of deriving induced pluripotent stem cell lines, and methods of deriving T cells from induced pluripotent stem cell lines.

Human T cell derived from T cell-derived induced pluripotent stem cell and methods of making and using

In one aspect, a method of treating a subject having or at risk of having graft-versus-host disease (GvHD) generally includes administering to the subject a plurality of myeloid-derived suppressor cells (MDSCs) effective to ameliorate at least one symptom or clinical sign of graft-versus-host disease compared to a suitable control subject. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject an anti-tumor therapy and co-administering to the subject an inflammasome inciting agent in an amount effective to increase inflammasome activation of MDSCs sufficiently to reduce suppressor function of the MDSCs.

Therapeutic methods involving modulating inflammasome activation of myeloid-derived suppressor cells

ILC2 cells play a role in the pathogenesis of graft versus host disease (GvHD) and idiopathic pneumonia syndrome (IPS), both conditions associated with allogeneic stem cell transplantation. Infusion of IL-33 activated ILC2 cells into patients with ongoing GvHD or IPS, or prior to onset of GvHD or IPS in susceptible patients, substantially ameliorates the disease and improves survival.

Compositions and methods for preventing and treating graft versus host disease

This disclosure provides miRNA/mRNA pairs that can be used to increase the efficacy of T cells or to down-modulate T cell efficacy and restore equilibrium.

Materials and methods for modifying the activity of T cells

The invention relates to treatment of graft versus host disease (GVHD) using compounds that inhibit ROCK2. In preferred aspects, the present invention provides methods for the treatment of GVHD, including chronic GVHD (cGVHD) using compounds having the formulae 1-XXV, as set forth herein.

Treatment of GVHD

Methods and compositions for increasing the suppressive function of regulatory T-cells (Tregs) are provided.

Methods and compositions for increasing the suppressive function of regulatory T-cells (Tregs)

The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.

TALEN-based gene correction

The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking or inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft vs host disease. The iTregs can also be used to treat autoimmune diseases.

Inducible regulatory t-cell generation for hematopoietic transplants

Methods of gene correction, methods of generating induced pluripotent stem cells (iPSCs), and methods of deriving multi-lineage cell types with therapeutic value. In some embodiments, the gene correction affects the expression and/or function of the functional type VII collagen protein (C7).

Method for correcting a genetic sequence

Talen-based gene correction

The present invention relates generally to methods to prepare NK and LTi-like, NK22 cells from HSCs and uses of those cells.

Generation of natural killer cells and lymphoid tissue inducer-like (LTi-like) NK-22 cells

Compositions and methods for the detection, prevention, or treatment of anthrax or other infectious diseases. In one aspect, the present invention provides methods for immunizing humans or animals againstor other capsulated pathogens. The methods include administering a capsular polypeptide of a pathogen of interest and a CD40 agonist to a human or animal. The capsular polypeptide or the CD40 agonist is administered in such an amount or frequency that an immunoprotective response can be elicited in the human or animal against the pathogen of interest. In another aspect, the present invention provides methods of using passive immunization with anti-capsular polypeptide antibodies to prevent or treat infections caused byor other pathogens. In yet another aspect, the present invention provides methods useful for diagnosis of anthrax by detection of capsular polypeptide in serum or other biological samples.

Detection, prevention, and treatment of anthrax and other infectious diseases

Inducible regulatory T-cell generation for hematopoietic transplants

Growing community of inventors

Golden Valley, MN, United States of America

Bruce Robert Blazar